Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Hyperion Therapeutics, Inc. Identifier:
First received: December 2, 2010
Last updated: July 12, 2013
Last verified: July 2013

The present protocol is a treatment protocol to allow continued use of HPN-100 for the treatment of UCD subjects who complete 12 months of treatment in Study HPN-100-005, HPN-100-007, or HPN-100-012. Under this protocol, long-term safety will continue to be assessed.

Condition Intervention Phase
Urea Cycle Disorders
Drug: HPN-100
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Long Term Use of HPN-100 in Urea Cycle Disorders

Resource links provided by NLM:

Further study details as provided by Hyperion Therapeutics, Inc.:

Primary Outcome Measures:
  • Rate of Adverse Events [ Time Frame: Every six months for 2 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Venous ammonia levels [ Time Frame: Every six months for two years ] [ Designated as safety issue: Yes ]
  • Number of hyperammonemic crises [ Time Frame: Every six months for two years ] [ Designated as safety issue: Yes ]
  • Neuropsychological testing [ Time Frame: Every twelve months for two years ] [ Designated as safety issue: Yes ]
    Wechsler Abbreviated Scale of Intelligence (WASI) The California Verbal Learning Test (CVLT) Digit Span The Child Behavior Checklist (CBCL) Behavior Rating Inventory of Executive Function® (BRIEF®)

  • Causes of hyperammonemic crises [ Time Frame: Every six month for two years ] [ Designated as safety issue: Yes ]

Enrollment: 88
Study Start Date: October 2010
Estimated Study Completion Date: June 2014
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: HPN-100
    HPN-100 will be administered orally three times daily (TID) with meals. The maximum recommended dose of HPN-100 in subjects weighing less than 20 kg is 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and is 11.48 mL/m2/day in heavier subjects (equivalent to 13g/m2/day of NaPBA). The maximum HPN-100 dose should be 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.

Ages Eligible for Study:   1 Year and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects who completed HPN-100-005, HPN-100-007, or HPN-100-012
  • Signed informed consent by subject and/or subject's legally authorized representative
  • Negative pregnancy test for all females of childbearing potential

Exclusion Criteria:

  • Any clinical or laboratory abnormality or medical condition that, at the discretion of the investigator, may put the subject at increased risk when participating
  • Known hypersensitivity to PAA or PBA
  • Liver transplant, including hepatocellular transplant
  • Pregnant, breastfeeding or lactating females
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01257737

United States, California
UCLA Pediatrics/Genetics
Los Angeles, California, United States
Stanford University School of Medicine
Palo Alto, California, United States
United States, Colorado
Denver Children's Hospital
Aurora, Colorado, United States
United States, District of Columbia
Children's National Medical Center
Washington, District of Columbia, United States
United States, Maine
Maine Medical Center
Portland, Maine, United States
United States, Minnesota
University of Minnesota Medical Center
Minneapolis, Minnesota, United States
United States, New York
Mount Sinai School of Medicine
New York, New York, United States
United States, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States
United States, Pennsylvania
Children's Hospital of Pittsburg of UPMC
Pittsburg, Pennsylvania, United States
United States, Texas
Baylor College of Medicine
Houston, Texas, United States
United States, Utah
University of Utah
Salt Lake City, Utah, United States
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States
United States, Wisconsin
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
Canada, Ontario
The Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8
Sponsors and Collaborators
Hyperion Therapeutics, Inc.
  More Information

No publications provided

Responsible Party: Hyperion Therapeutics, Inc. Identifier: NCT01257737     History of Changes
Other Study ID Numbers: HPN-100-011
Study First Received: December 2, 2010
Last Updated: July 12, 2013
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board
Canada: Health Canada

Keywords provided by Hyperion Therapeutics, Inc.:
Urea Cycle Disorders
Sodium Phenylbutyrate
Glyceryl tri-(4-phenylbutyrate)

Additional relevant MeSH terms:
Urea Cycle Disorders, Inborn
Amino Acid Metabolism, Inborn Errors
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Central Nervous System Diseases
Genetic Diseases, Inborn
Metabolic Diseases
Metabolism, Inborn Errors
Nervous System Diseases processed this record on March 03, 2015